Multimodal Chromatography-based Therapeutic and Diagnostic Platform

This inventive concept leverages the core technology of multimodal chromatography for the purification of proteins, expanding its application to new industries, including neurodegenerative disease treatment, cancer therapy, and disease diagnosis.

The original patent disclosed a multimodal chromatography method for purifying HIV-1 envelope glycoprotein. However, the technology's potential extends beyond this specific application. The inventive concept addresses the need for efficient and effective protein purification methods in various fields, where the original patent's limitations are overcome by adapting the technology to new use cases.

The new inventive concept comprises a multimodal chromatography-based platform for purifying proteins, which can be used in various therapeutic and diagnostic applications. The platform consists of a multimodal resin, a buffer system, and a pump for flowing the buffer through the column. The protein of interest is captured on the multimodal resin and eluted in a buffer suitable for administration to a patient or for use in diagnostic assays. The system can be used for treating neurodegenerative diseases, cancer, and other diseases, as well as for diagnosing diseases using multimodal chromatography-purified proteins.

The new claims introduce novel applications and use cases for the multimodal chromatography technology, which were not originally considered in the context of HIV-1 envelope glycoprotein purification. The inventive step lies in the adaptation of the core technology to new industries and fields, providing a significant expansion of its potential impact.

Alternative embodiments of the inventive concept may include different types of multimodal resins, buffer systems, and pump configurations. Variations may also include the use of different protein targets, disease indications, or diagnostic assays. Additionally, the platform could be integrated with other technologies, such as microfluidics or biosensors, to enhance its functionality and versatility.

The multimodal chromatography-based therapeutic and diagnostic platform has significant commercial potential in various industries, including pharmaceuticals, biotechnology, and diagnostics. The platform's adaptability to different protein targets and disease indications makes it an attractive solution for companies seeking to develop new therapies and diagnostic tools. The target market includes pharmaceutical companies, biotech startups, and diagnostic companies seeking to develop innovative solutions for unmet medical needs.